MICURERX

Originally founded in 2013 with technology spun out of the Weizmann Institute of Science, miCure leverages its deep understanding of the role of microRNAs in the biology of psychiatric diseases. More recently, the company has expanded its scientific and technological scope to include neurodegenerative and neurologic diseases, as well as other classes of RNAi therapeutics and novel methods to deliver oligonucleotides to the CNS.

Also known as: miCure Therapeutics, miCure Therapeutics Ltd.